Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade A 188.07 1.27% 2.35
VRTX closed up 1.27 percent on Friday, February 15, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical VRTX trend table...

Date Alert Name Type % Chg
Feb 15 Crossed Above 20 DMA Bullish 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 15 Up 4 Days in a Row Strength 0.00%
Feb 15 Up 5 Days in a Row Strength 0.00%
Feb 14 Outside Day Range Expansion 1.27%
Feb 14 Up 3 Days in a Row Strength 1.27%
Feb 14 Up 4 Days in a Row Strength 1.27%
Feb 14 Up 5 Days in a Row Strength 1.27%
Feb 13 Narrow Range Bar Range Contraction 1.52%
Feb 13 NR7 Range Contraction 1.52%

Older signals for VRTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Chemistry Chemical Compounds Organic Compounds Infection Influenza Cystic Fibrosis Serious Diseases Cyclopropanes Autoimmune Disease Breakthrough Therapy Hepatitis C Virus Organofluorides Treatment Of Cystic Fibrosis Hcv Infection
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 195.81
52 Week Low 144.07
Average Volume 1,499,128
200-Day Moving Average 172.3567
50-Day Moving Average 178.0996
20-Day Moving Average 187.084
10-Day Moving Average 184.349
Average True Range 4.484
ADX 16.95
+DI 24.981
-DI 19.7896
Chandelier Exit (Long, 3 ATRs ) 182.358
Chandelier Exit (Short, 3 ATRs ) 191.852
Upper Bollinger Band 194.8743
Lower Bollinger Band 179.2937
Percent B (%b) 0.56
BandWidth 8.328131
MACD Line 1.4068
MACD Signal Line 2.0418
MACD Histogram -0.635
Fundamentals Value
Market Cap 47.42 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 180.84
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 192.41
Resistance 3 (R3) 192.09 190.32 191.68
Resistance 2 (R2) 190.32 189.22 190.48 191.44
Resistance 1 (R1) 189.20 188.54 189.76 189.52 191.20
Pivot Point 187.43 187.43 187.72 187.59 187.43
Support 1 (S1) 186.31 186.33 186.87 186.63 184.94
Support 2 (S2) 184.54 185.65 184.70 184.70
Support 3 (S3) 183.42 184.54 184.46
Support 4 (S4) 183.74